Zhenya Lindgardt Sells 26,867 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERAGet Free Report) CEO Zhenya Lindgardt sold 26,867 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $8.11, for a total value of $217,891.37. Following the sale, the chief executive officer now directly owns 869,245 shares in the company, valued at $7,049,576.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Zhenya Lindgardt also recently made the following trade(s):

  • On Wednesday, May 8th, Zhenya Lindgardt sold 11,992 shares of Sera Prognostics stock. The shares were sold at an average price of $9.59, for a total value of $115,003.28.
  • On Tuesday, March 26th, Zhenya Lindgardt sold 38,899 shares of Sera Prognostics stock. The shares were sold at an average price of $9.37, for a total value of $364,483.63.

Sera Prognostics Stock Down 2.2 %

Sera Prognostics stock opened at $8.04 on Friday. Sera Prognostics, Inc. has a one year low of $1.52 and a one year high of $12.35. The business’s fifty day moving average is $9.37 and its 200 day moving average is $7.90.

Sera Prognostics (NASDAQ:SERAGet Free Report) last announced its earnings results on Wednesday, May 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). Sera Prognostics had a negative return on equity of 46.35% and a negative net margin of 11,843.79%. As a group, research analysts anticipate that Sera Prognostics, Inc. will post -0.94 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, William Blair reaffirmed an “outperform” rating on shares of Sera Prognostics in a research report on Friday, May 10th.

View Our Latest Stock Report on SERA

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. StepStone Group LP purchased a new position in Sera Prognostics in the fourth quarter worth about $61,000. Sanders Morris Harris LLC purchased a new position in Sera Prognostics in the first quarter worth about $174,000. CWM LLC purchased a new position in Sera Prognostics in the fourth quarter worth about $242,000. Resource Consulting Group Inc. purchased a new position in Sera Prognostics in the fourth quarter worth about $265,000. Finally, Vanderbilt University purchased a new position in Sera Prognostics in the fourth quarter worth about $284,000. 54.64% of the stock is owned by hedge funds and other institutional investors.

About Sera Prognostics

(Get Free Report)

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

See Also

Insider Buying and Selling by Quarter for Sera Prognostics (NASDAQ:SERA)

Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.